This study identified a novel potential therapeutic, ANB-504, utilizing our human-focused discovery paradigm. ANB-504 inhibits the activation of human sensory neurons in pathological states and had undetectable effect on the human cardiac action potential with an excellent safety margin to cardiac contractility risk.

AUTHORS: Andre Ghetti, Anh Tuan Ton, Yannick Miron, Phachareeya Ratchada, Nathalie Nguyen, Ashley Alamillo, William Nguyen, Katrina Sweat, Brynna Nguyenton, Tim Indersmitten, Guy Page, Paul Miller, Najah Abi-Georges and Jack Reynolds